| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/16/2005 | EP1505974A2 Use of compounds that are effective as selective opiate receptor modulators |
| 02/16/2005 | EP1505973A2 Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
| 02/16/2005 | EP1505972A2 A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases |
| 02/16/2005 | EP1505971A2 Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| 02/16/2005 | EP1505970A1 Methods of using thiazolidine derivatives to treat cancer or inflammation |
| 02/16/2005 | EP1505969A2 Pharmaceutical compositions and methods of using c-21 modified epothilone derivatives |
| 02/16/2005 | EP1505968A1 Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes |
| 02/16/2005 | EP1505967A1 Method for treating obesity |
| 02/16/2005 | EP1505966A1 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors |
| 02/16/2005 | EP1505965A1 Use of valsartan ot its metabolite to inhibit platelet aggregation |
| 02/16/2005 | EP1505964A1 Annelated pyrrole compounds as proton pump inhibitors for treating ulcer |
| 02/16/2005 | EP1505963A1 Hepatitis c virus inhibitors |
| 02/16/2005 | EP1505962A2 Monotherapy for the treatment of parkinson's disease with cyclooxygenase-2 (cox 2) inhibitor(s) |
| 02/16/2005 | EP1505960A1 Methods of treating gastrointestinal and genitourinary pain disorders using vinlafaxin and derivatives |
| 02/16/2005 | EP1505959A1 Use of edg receptor binding agents in cancer |
| 02/16/2005 | EP1505958A2 Coenzyme q products exhibiting high dissolution qualities |
| 02/16/2005 | EP1505957A1 Matrix type patch containing bronchodilators |
| 02/16/2005 | EP1505956A1 A method to improve surface properties of pharmaceutical tablets |
| 02/16/2005 | EP1505955A1 Short chain polymer for enhancing the bioadhesiveness of polymers on mucosal membrane |
| 02/16/2005 | EP1505953A2 Novel polyol-glycoside compositions for the skin |
| 02/16/2005 | EP1505951A1 Tooth whitening products |
| 02/16/2005 | EP1505948A1 Reduction of hair growth |
| 02/16/2005 | EP1505945A2 Substituted cycloalkyl p1' hepatitis c virus inhibitors |
| 02/16/2005 | EP1505942A2 Pathogen vaccines and methods for using the same |
| 02/16/2005 | EP1505930A2 Drug-delivery endovascular stent and method for treating restenosis |
| 02/16/2005 | EP1505873A2 Universal chimera bank |
| 02/16/2005 | EP1425582A4 Diagnostic markers for ischemia |
| 02/16/2005 | EP1425258A4 Hydroxyeicosenoic acid analogs |
| 02/16/2005 | EP1421099B1 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents |
| 02/16/2005 | EP1397365B1 Heteroaryl-diazabicyclo-alkanes as cns-modulators |
| 02/16/2005 | EP1395553B1 Pyrrolidine derivatives as factor xa inhibitors |
| 02/16/2005 | EP1377584B1 Novel cyclohexenyl phenyl diazepines as vasopressin and oxytocin receptor modulators |
| 02/16/2005 | EP1339675B1 Ortho-substituted and meta-substituted bis-aryl compounds, method for the production thereof, their use as a medicament, and pharmaceutical preparations containing these compounds |
| 02/16/2005 | EP1311519A4 Thermosensitive cyclotriphosphazene-platinum complex conjugate, its preparation method and anticancer agent containing the same |
| 02/16/2005 | EP1296698A4 Therapeutic agents - ii |
| 02/16/2005 | EP1296697A4 Therapeutic agents - i |
| 02/16/2005 | EP1281709B1 Novel heterocyclic compounds with anti-inflammatory activity |
| 02/16/2005 | EP1268463B1 Polycyclic aryl and heteroaryl substituted 4-pyrones useful for selective inhibition of the coagulation cascade |
| 02/16/2005 | EP1267849B1 Restricting reinstatement of drug use |
| 02/16/2005 | EP1253917B1 Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments |
| 02/16/2005 | EP1246814B1 Compounds and methods for modulation of estrogen receptors |
| 02/16/2005 | EP1246792A4 Compounds and compositions for delivering active agents |
| 02/16/2005 | EP1244617B1 Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone |
| 02/16/2005 | EP1240166B1 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl carboxamide inhibitors of cyclin dependent kinases |
| 02/16/2005 | EP1231915B1 Use of pleuromutilin derivatives for transdermal treatment of bacterial diseases |
| 02/16/2005 | EP1215203B1 Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient |
| 02/16/2005 | EP1197223B1 Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy |
| 02/16/2005 | EP1181329B1 Silicone gel containing salicylic acid |
| 02/16/2005 | EP1140005B1 Utilization of an extract of a plant of the cecropia genus |
| 02/16/2005 | EP1068200B1 2,4,4-trisubstituted-1,3-dioxolane antifungals |
| 02/16/2005 | EP1064285B1 Novel cephalotaxane derivatives and process for their preparation |
| 02/16/2005 | EP1042347A4 Dna pharmaceutical formulations comprising citrate or triethanolamine and combinations thereof |
| 02/16/2005 | EP1021184B1 Use of flunarizine for the topical treatment of ocular hypertension |
| 02/16/2005 | EP0986540B1 The use of carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones as sodium channel blockers |
| 02/16/2005 | EP0966284B1 Starter kit containing nicotinic acid compositions |
| 02/16/2005 | EP0957926B1 Oligonucleotide compositions and methods for the modulation of the expression of b7 protein |
| 02/16/2005 | EP0944610B1 Asymmetric synthesis of benzoxazinones |
| 02/16/2005 | EP0833643B1 Anhydrous alendronate monosodium salt formulations and their use for the treatment of bone diseases |
| 02/16/2005 | EP0769026B2 Fractionated polydisperse compositions |
| 02/16/2005 | EP0634896B1 Evaluation of patients with progressive immunosuppression |
| 02/16/2005 | CN1582522A Intelligent serial cell charger and charging circuit block |
| 02/16/2005 | CN1582296A Template-fixed peptidomimeticsas inhibitors of serine proteases |
| 02/16/2005 | CN1582288A Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1 |
| 02/16/2005 | CN1582287A Thiophenylthiopyrane dioxides as MMP or TNF-alpha inhibitors |
| 02/16/2005 | CN1582285A Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (GSK3 inhibitors) |
| 02/16/2005 | CN1582284A Aminopyrimidines and pyridines |
| 02/16/2005 | CN1582283A Benzothiepine ileal bile acid transport inhibitors |
| 02/16/2005 | CN1582282A Novel mandelate salts of substituted tetracyclic tetrahydrofuran derivatives |
| 02/16/2005 | CN1582281A Mch受体拮抗剂 Mch receptor antagonist |
| 02/16/2005 | CN1582280A 3, 4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| 02/16/2005 | CN1582279A Peroxisome proliferator activated receptor agonists |
| 02/16/2005 | CN1582278A Polymorphous form of rimonabant, preparation method and pharmaceutical compositions containing same |
| 02/16/2005 | CN1582277A Amide derivatives as glycogen synthase kinase 3-beta inhibitors |
| 02/16/2005 | CN1582276A Phenylalanine enamide derivatives |
| 02/16/2005 | CN1582275A Calcium antagonistic compound |
| 02/16/2005 | CN1582274A Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| 02/16/2005 | CN1582271A Inhibitors of integrin alpha v beta 6 |
| 02/16/2005 | CN1582269A Hydroxyeicosenoic acid analogs |
| 02/16/2005 | CN1582172A Treating canker sores with patches to speed healing and relieve pain |
| 02/16/2005 | CN1582170A Parenteral composition of paracetamol |
| 02/16/2005 | CN1582169A Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions |
| 02/16/2005 | CN1582168A Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 02/16/2005 | CN1582167A Cytokine-inducing material and cytokine-inducing tool |
| 02/16/2005 | CN1582166A Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| 02/16/2005 | CN1582165A Antibodies to CD40 |
| 02/16/2005 | CN1582161A Pharmatceutical Formualtion comprising cyclosporin and use thereof |
| 02/16/2005 | CN1582160A Novel herbal chemical composition for treatment of cancer |
| 02/16/2005 | CN1582159A Preparing material of flavanol wood lipid with increased solubility |
| 02/16/2005 | CN1582158A Novel therapeutic indication of azithromycin for treatment of non-infective inflammatory diseases |
| 02/16/2005 | CN1582157A Rehydrating formulation |
| 02/16/2005 | CN1582156A Methods for treating ocular neovascular diseases |
| 02/16/2005 | CN1582155A Ribavirin syrup formulations |
| 02/16/2005 | CN1582154A Method for treating or prophylaxis of aldo sterone-medicated phthogenic effects in subjwect using epoxy-steroidal aldosterone antagonist |
| 02/16/2005 | CN1582153A Use of (11beta, 17beta)-11-(1, 3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4, 9-dien-3-one in the treatment of major depressive disorder |
| 02/16/2005 | CN1582152A composition of estrogen and other hormons with ascorbate, lysine, proline and other substances |
| 02/16/2005 | CN1582151A Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibitory activity for the treatment hyperlipidaemia |
| 02/16/2005 | CN1582150A Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity |
| 02/16/2005 | CN1582149A Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels |
| 02/16/2005 | CN1582148A Derivatives of phenoxy-n-'4-(isothiazolidin-1, 1-dioxid-2yl)pheny!-valerian- acid amide and other compounds as inhibitors of the coagulation factor Xa in the treatment of thromboembolic diseases and tu |
| 02/16/2005 | CN1582147A Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them |